FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 33 of 34
Jan 11, 2026The National Institutes of Health (NIH), a cornerstone of biomedical research and public health advancement, is currently facing a critical juncture as four leading officials have publicly resigned. Their departure raises important questions about scientific independence and institutional integrity amid alleged interference and censorship within the agency.
TCB Team
Jan 11, 2026The National Institutes of Health (NIH) has been a cornerstone of biomedical research innovation and public health advancement. However, recent resignations by four senior leaders spotlight serious concerns over editorial interference and censorship, raising questions about the organization's commitment to scientific rigor and transparency. This development underscores a growing apprehension within the biomedical community regarding governance and autonomy at one of the world's premier research institutions.
TCB Team
Jan 9, 2026The study highlights consequential public health impacts stemming from policy changes, underlining critical gaps in preventive cancer care access for vulnerable populations.
TCB Team
Jan 8, 2026With increasing backing from House Republicans, particularly those representing vulnerable districts, the subsidy extension aims to ease rising insurance premium costs. This development marks a pivotal moment in ongoing healthcare policy negotiations for 2026.
TCB Team
Jan 8, 2026A recently published study in Science attributes the sharp decline in overdose fatalities to changes in the fentanyl supply, highlighting implications for public health strategies addressing the opioid crisis.
TCB Team
Jan 8, 2026The court's decision pauses the rollout of a controversial pilot that aimed to reform drug pricing for hospitals under the 340B program. This legal development underscores persistent challenges in federal drug rebate policies.
TCB Team
Jan 8, 2026The investigation focuses on potential limitations imposed by UnitedHealth on hospitalizations, which could affect patient health outcomes and adherence to Medicare regulations. This expands ongoing scrutiny of managed care practices.
TCB Team
Jan 8, 2026This policy shift by the FDA signals a new era of deregulation to promote AI use in healthcare technologies, balancing innovation with appropriate safeguards.
TCB Team
Jan 8, 2026New policy shifts by the U.S. FDA seek to deregulate AI-enabled medical devices and wearables to promote innovation and integration within healthcare, marking a significant regulatory pivot in digital health oversight.
TCB Team
Jan 7, 2026The latest dietary guidelines recommend increased protein and dairy consumption while reducing sugar and processed food intake. However, scrutiny arises due to the advisory panel's financial ties to industries that benefit from these changes. This controversy comes amid criticism from figures like Robert F. Kennedy Jr. regarding corporate influence in public health policies.
TCB Team
Jan 6, 2026In a significant policy shift aimed at accelerating innovation and access, the FDA will reduce its regulatory burden on AI-powered and wearable health technology. This move reflects a strategic decision to facilitate the expansion of AI use in healthcare while balancing safety and efficacy.
TCB Team
Jan 6, 2026In a recent regulatory update, the FDA declined approval of Sanofi’s tolebrutinib for a specific form of multiple sclerosis, citing concerns relating to toxicities and ambiguous clinical efficacy. This decision presents a significant hurdle for the therapy's development.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.